Patrick Darken
- Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparatorsBy Leonardo Fabbri, Roberto Rodriguez-Roisin, Chadwick Orevillo, Carlos Fernandez, Patrick Darken, Earl St. Rose, Christine Kollar and Colin ReisnerLeonardo Fabbri1Department of Medical and Surgical Specialties, Section of Respiratory Diseases, University of Modena and Reggio Emilia, Modena, ItalyRoberto Rodriguez-Roisin2Servei De Pneumologia (ICT), Hospital Clínic, Universitat De Barcelona, Barcelona, SpainChadwick Orevillo3Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesCarlos Fernandez3Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesPatrick Darken3Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesEarl St. Rose3Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesChristine Kollar4Biostatistics, Everest Clinical Research, Inc, Little Falls, NJ, United StatesColin Reisner3Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United States
- Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III developmentBy Colin Reisner, Chadwick Orevillo, Carlos Fernandez, Patrick Darken, Earl St. Rose, Michael Golden, Tracy Fischer, Shannon Strom, Christine Kollar and K.F. RabeColin Reisner1Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesChadwick Orevillo1Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesCarlos Fernandez1Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesPatrick Darken1Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesEarl St. Rose1Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesMichael Golden2Regulatory Affairs, Pearl Therapeutics, Inc., Redwood City, CA, United StatesTracy Fischer2Regulatory Affairs, Pearl Therapeutics, Inc., Redwood City, CA, United StatesShannon Strom2Regulatory Affairs, Pearl Therapeutics, Inc., Redwood City, CA, United StatesChristine Kollar3Biostatistics, Everest Clinical Research Services, Inc., Little Falls, NJ, United StatesK.F. Rabe4Dept of Medicine University Kiel, And LungenClinic, Grosshansdorf, Germany
- Pearl's PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003By Colin Reisner, Carlos Fernandez, Patrick Darken, Paolo DePetrillo, Earl St. Rose, Tracy Fischer, Shannon Strom, Michael Kong, Kar Wong, Shahid Siddiqui, Greg Tardie and Chadwick OrevilloColin Reisner1Clinical Development, Pearl Therapeutics, Morristown, NJ,Carlos Fernandez1Clinical Development, Pearl Therapeutics, Morristown, NJ,Patrick Darken1Clinical Development, Pearl Therapeutics, Morristown, NJ,Paolo DePetrillo2Clinical Services, SNBL Clinical Pharmacology Center, Baltimore, MD,Earl St. Rose1Clinical Development, Pearl Therapeutics, Morristown, NJ,Tracy Fischer3Regulatory Affairs, Pearl Therapeutics, Raleigh, NC,Shannon Strom3Regulatory Affairs, Pearl Therapeutics, Raleigh, NC,Michael Kong4Biostatistics, Everest Clinical Research Services, Inc., Markham, ON, CanadaKar Wong4Biostatistics, Everest Clinical Research Services, Inc., Markham, ON, CanadaShahid Siddiqui1Clinical Development, Pearl Therapeutics, Morristown, NJ,Greg Tardie1Clinical Development, Pearl Therapeutics, Morristown, NJ,Chadwick Orevillo1Clinical Development, Pearl Therapeutics, Morristown, NJ,
- LATE-BREAKING ABSTRACT: PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPDBy Klaus Rabe, Fernando Martinez, Roberto Rodriguez-Roisin, Leonardo M. Fabbri, Gary T. Ferguson, Paul Jones, Stephen Rennard, Michael Golden, Patrick Darken, Chad Orevillo, Tracy Fischer and Colin ReisnerKlaus Rabe1Lungen Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, GermanyFernando Martinez2Department of Internal Medicine, Weill Cornell Medical College, New York, NY United StatesRoberto Rodriguez-Roisin3Servei de Pneumologia, Institut del Tòrax, Hospital Clinic-IDIBAPS-CIBERES, Barcelona, SpainLeonardo M. Fabbri4Department of Oncology, Haematology and Respiratory Diseases, University of Modena, Modena, ItalyGary T. Ferguson5COPD, Pulmonary Research Institute of Southeast Michigan, Livonia, MI United StatesPaul Jones6Institute for Infection and Immunity, St. George's, University of London, London, United KingdomStephen Rennard7Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, NE United StatesMichael Golden8Clinical Development and Medical Affairs, Pearl Therapeutics Inc., Morristown, NJ United StatesPatrick Darken8Clinical Development and Medical Affairs, Pearl Therapeutics Inc., Morristown, NJ United StatesChad Orevillo8Clinical Development and Medical Affairs, Pearl Therapeutics Inc., Morristown, NJ United StatesTracy Fischer8Clinical Development and Medical Affairs, Pearl Therapeutics Inc., Morristown, NJ United StatesColin Reisner8Clinical Development and Medical Affairs, Pearl Therapeutics Inc., Morristown, NJ United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.